Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 20Breast 6Thoracic 5Sarcoma 4Genitourinary 4Head & Neck 3Gynecologic 3Gastrointestinal 3Plasma cell 1Other solid neoplasm 1Lymphoid 1

Conditions

Neoplasms, Plasma Cell 3Urinary Bladder Neoplasms 1Smoldering Multiple Myeloma 1Sarcoma 1Ovarian Neoplasms 1Melanoma 1Esophageal Neoplasms 1Chondrosarcoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

fludarabine 3Cyclophosphamide 3Specimen Handling 2Magnetic Resonance Spectroscopy 2zimberelimab 1ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1temsirolimus 1sapanisertib 1resiquimod 1relatlimab 1poly ICLC 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1marizomib 1larotrectinib 1ipatasertib 1interferon-alfa-1b 1erdafitinib 1defactinib 1dabrafenib 1copanlisib 1cobimetinib 1cc-486 1capivasertib 1binimetinib 1adavosertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × poly ICLC × Plasma cell × Clear all
NCT00948961 2016-06-27

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Celldex Therapeutics

Phase 1/2 Completed
70 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡